HMO physician applauds Spitzer’s focus on information bias / NYT blind spot Sun, 20 Jun 2004 The affirmation by a Kaiser Permanente physician, Dr. Kate Scannell, that NYS Attorney General, Eliot Spitzer, deserves applause for his “bold and courageous” lawsuit, is an encouraging watershed. The suit, she says, “gives me…
Member of UK Parliament Accuses Drugs Giant of ‘Voodoo Medicine’ – Scotsman Wed, 25 Feb 2004 Paul Flynn, Member of UK Parliament raised the antidepressant drug scandal in Parliament, focusing on the British drug manufacturer giant, GlaxoSmithKline (GSK). “The Seroxat [Paxil] scandal is one of gigantic proportions that affects millions…
GSK Sales Reps told NOT to Divulge Paxil Data / Merck Withdraws Vioxx Thu, 30 Sep 2004 The Associated Press reports: “Merck pulled Vioxx after admitting studies showed the drug raised the risk of heart attack. As recently as August, Merck “strongly” disagreed with studies showing the drug increased heart…
Expert FDA Report: SSRI Suicide risk_SF Chronicle / NYT/ NJ Ledger/ AP Fri, 16 Apr 2004 FDA officials have provoked congressional hearings at which they will have to explain, not only why they concealed data linking antidepressants to increased violent and suicidal behavior, and why they covered up a report…
Doctor Chides Medical Societies to Take Action – GSK Fined $150 Million in Medicare Fraud Wed, 21 Sep 2005 The latest in a series of fraud settlements, GlaxoSmithKline has agreed to pay $150 million to settle fraud allegations over inflating price of Zorfran and Kytril (nausea drugs) when billing Medicare…
Infomail 2005 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Subscribe to the AHRP infomail list Dec 16: Drugs, Devices & Doctors – NYT Paul Krugman Dec 11: Scientific Fraud & Corruption on Both sides of Atlantic: Merck / Proctor & Gamble Dec 11: Gov Accountability…
GlaxoSmithKline CEO: “We had to absorb a number of hits” Mon, 16 Feb 2004 Antidepressant drug safety issues are beginning to have a financial impact. Dow Jones reports: “GlaxoSmithKline PLC said its net income fell 6% in the fourth quarter, hurt by previously announced legal costs related to its anti-inflammatory…
National Assoc School Psychologists Communiqué Re: Paxil, SSRIs Thu, 18 Dec 2003 In a Communiqué to its membership about regulatory action to protect children from the hazards of Paxil and other antidepressants, The National Association of School Psychologists acknowledges the leading role played by The Alliance for Human Research Protection…
New York Times Editorial Gets it Right: When Drug Companies Hide Data Sun, 6 Jun 2004 At last, the New York Times editorial board has come to recognize that: “drug companies should be forced to make public the results of all of their clinical trials the moment they are completed,…
Advisory Committee tells FDA: strengthen warnings on SSRI drug labels now Wed, 4 Feb 2004 On February 2, more than 60 families and children from all across America testified at a public FDA advisory committee hearing describing (in 2 minutes) how their children suffered drug-induced harm after being prescribed an…
Additional information as of late Wed Oct 19: Although I was assured that attendance for a presentation by Dr. David Healy (at Columbia University School of Public Health on Oct. 20 at 12:30) would be open to the public, a problem seems to have emerged after an AHRP Infomail about…
Data from Unpublished Trials Suggest that Most SSRI Antidepressant Drugs Unsuitable for Children Wed, 21 Apr 2004 An independent analysis in next week’s The Lancet compares the published and unpublished data of pediatric SSRI antidepressant clinical trial data, finding the published reports not to be evidence-based. “In a global medical…
